2. Endocrinology

Endocrinology

Endocrinology

Related Products

PDF 21.44 MB

Found in most species of the animal kingdom, the endocrine system consists of glands that secrete hormones, and receptors that detect and react to the hormones. In response to environmental stimuli, the endocrine system secretes hormones and uses them as chemical messengers to orchestrate physiological, developmental and reproductive changes that affect the entire body for a long period of time. In order to maintain the proper functioning of the body through its entire life cycle, the endocrine system utilizes a complex feedback mechanism to fine-tune the balance of hormones in the bloodstream. Even a slight disruption to endocrine system’s function can throw off the delicate balance of hormones in the human body and lead to an endocrine disorder, or endocrine disease, such as diabetes, adrenal insufficiency, hyper- or hypothyroidism, and polycystic ovary syndrome (PCOS).

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161618
    MJ04 2099014-23-8 98.08%
    MJ04 is a selective inhibitor for Janus Kinase 3 (JAK 3) with an IC50 of 2.03 nM. MJ04 inhibits T cell differentation and inhibits the proinfammatory cytokines in Lipopolysaccharides (HY-D1056)‑induced macrophages. MJ04 exhibits good pharmacokinetic characters in mice, promotes hair growth in DHT-induced androgenetic alopecia (AGA) in athymic mice model, without significant toxicity (LD50 >2 g/kg).
    MJ04
  • HY-163121
    PST3.1a 1096144-06-7 98%
    PST3.1a is an orally active and brain-penetrant N-acetylglucosamine glycosyltransferase (MGAT5) inhibitor with a human IC50 of 2 µM. PST3.1a inhibits TGFβR and FAK signaling pathway activity. PST3.1a alters β1,6-GlcNAc N-glycans and microtubule/microfilament integrity, increases OLIG2 expression, and inhibits proliferation, migration, invasiveness, and clonogenic capacities of glioblastoma initiating cells. PST3.1a reduces invasive and proliferative capacity of glioblastoma initiating cells in orthotopic graft models, increases overall survival of orthotopic graft model mice. PST3.1a blunts MGAT5 overexpression, decreases renal fibrosis via collagen 1, collagen 4, and galectin 3 downregulation in a rat chronic kidney disease model. PST3.1a can be used for the research of glioblastoma multiforme and chronic kidney disease.
    PST3.1a
  • HY-16346S
    Netupitant-d6 2070015-31-3 ≥98.0%
    Netupitant-d6 is the deuterium labeled Netupitant (CID-6451149), which is a highly potent and selective, orally active neurokinin-1 (NK1) receptor antagonist.
    Netupitant-d6
  • HY-16718A
    Dagrocorat hydrochloride 1044535-61-6 99.85%
    Dagrocorat (PF-00251802) hydrochloride is an orally active and selective high-affinity partial agonist of the glucocorticoid receptor. Dagrocorat hydrochloride is also a time-dependent reversible inhibitor of CYP3A (IC50=1.3 μM in human liver microsomes) and CYP2D6 (Ki=0.57 μM in human liver microsomes). Dagrocorat hydrochloride can be used for the research of rheumatoid arthritis.
    Dagrocorat hydrochloride
  • HY-171048
    GTx-027 928122-40-1 99.61%
    GTx-027 is an orally active and non-steroidal selective androgen receptor modulator (SARM). GTx-027 shows androgen receptor (AR) transactivation effects with the EC50 of 1.8 nM. GTx-027 acts selectively increase muscle weight (anabolic) without affecting secondary sexual organs (androgenic). GTx-027 has the protential for the study of breast cancer and stress urinary incontinence (SUI).
    GTx-027
  • HY-172774
    TRPV1 antagonist 10 896584-55-7 98.54%
    TRPV1 antagonist 10 is an orally active and potent TRPV1 antagonist (IC50 = 33.06 nM), moderate to weak URAT1 (IC50 = 22.51 μM) and GLUT9 (60.25% at 50 μM) inhibitor. TRPV1 antagonist 10 has analgesic and urate-lowering effect. TRPV1 antagonist 10 can be studied for research in hyperuricemia and inflammatory pain.
    TRPV1 antagonist 10
  • HY-173191
    SK-124 2760404-50-8
    SK-124 is an orally active, selective SIK2/SIK3 inhibitor. SK-124 inhibits SIK2 and SIK3. SK-124 increases P1NP and CTX. SK-124 increases bone formation and bone mass.
    SK-124
  • HY-17501S
    Bambuterol-d9 hydrochloride 1794810-59-5 99.88%
    Bambuterol-d9 (hydrochloride) is the deuterium labeled Bambuterol. Bambuterol ((±)-Bambuterol) hydrochloride is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline.
    Bambuterol-d9 hydrochloride
  • HY-17505R
    Candesartan Cilexetil (Standard) 145040-37-5 99.56%
    Candesartan Cilexetil (Standard) is the analytical standard of Candesartan Cilexetil. This product is intended for research and analytical applications. Candesartan Cilexetil (TCV-116) is an angiotensin II receptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure.
    Candesartan Cilexetil (Standard)
  • HY-176745
    SW016789 292613-04-8 99.85%
    SW016789 is a hypersecretion-inducer targeting VDAC1. SW016789 can induce insulin hypersecretion and Ca2+ influx in β-cells directly. SW016789 induces a transient endoplasmic reticulum stress response (ER stress), but does not cause beta cell death. SW016789 has reversible and non-apoptotic characteristics. SW016789 can be used for the study of Diabetes mellitus type 2 (T2DM) β-cell dysfunction.
    SW016789
  • HY-180107
    H36-E4 688310-17-0 98.57%
    H36-E4 is a WW domain containing E3 ubiquitin 27 protein ligase 2 (WWP2) inhibitor with a KD of 6.25 μM. H36-E4 inhibits WWP2 expression, restores the succinate dehydrogenase complex subunit C (SDHC) level, and defers the acute kidney injury (AKI)-to-chronic kidney disease (CKD) transition in unilateral kidney ischemia-reperfusion (UIR) mice. H36-E4 can be used for AKI-to-CKD transition research.
    H36-E4
  • HY-181555
    IACS-56676 3105153-34-9 98%
    IACS-56676 is a selective NRASG12D inhibitor with a target IC50 of 0.031 μM. IACS-56676 stabilizes the p-loop, maintains key interactions with Asp12, Gly60 and Asp69, and achieves selectivity against wild-type KRAS through substitution targeting Leu95. IACS-56676 can be used in the research of melanoma, hematologic malignancies and thyroid cancer.
    IACS-56676
  • HY-18204R
    Valsartan (Standard) 137862-53-4 99.95%
    Valsartan (Standard) is the analytical standard of Valsartan. This product is intended for research and analytical applications. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
    Valsartan (Standard)
  • HY-18754A
    FR 167653 158876-66-5 99.87%
    FR 167653 (FR 167653 sulfate), an orally active and selective p38 MAPK inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity. FR 167653 (FR 167653 sulfate) is effective in treating inflammation, relieving trauma and ischemia-reperfusion injury in vivo.
    FR 167653
  • HY-19513A
    MB-07344 sodium 99.30%
    MB-07344 sodium is a potent thyroid hormone receptor (TR)-β agonist with a Ki of 2.17 nM. MB-07344 sodium has additive cholesterol lowering activity in combination with Atorvastatin (HY-B0589) in rabbits, dogs and monkeys.
    MB-07344 sodium
  • HY-30215R
    (S)-Leucic acid (Standard) 13748-90-8
    (S)-Leucic acid (Standard) is the analytical standard of (S)-Leucic acid (HY-30215). This product is intended for research and analytical applications. (S)-Leucic acid is a metabolite of Leucine. (S)-Leucic acid has anabolic effects, particularly promoting muscle protein synthesis. (S)-Leucic acid can be used in the diagnosis of pregnancy loss.
    (S)-Leucic acid (Standard)
  • HY-A0014S
    Ramelteon-d5 1134159-63-9 99.83%
    Ramelteon-d5 is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation.
    Ramelteon-d5
  • HY-A0070C
    Liothyronine hydrochloride 6138-47-2 98%
    Liothyronine hydrochloride is an active form of thyroid hormone. Liothyronine hydrochloride is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively.
    Liothyronine hydrochloride
  • HY-B0010S
    Formoterol-d6 1020719-45-2 98%
    Formoterol-d6 is the deuterium labeled Formoterol. Formoterol ((±)Formoterol) is a potent, selective and long-acting β2-adrenoceptor agonist.
    Formoterol-d6
  • HY-B0154S
    Fluticasone propionate-d3
    Fluticasone propionate-d3 is the deuterium labeled Fluticasone propionate. Fluticasone propionate, a potent topical anti-inflammatory corticosteroid, is a selective glucocorticoid receptor agonist, with an absolute affinity (KD) of 0.5 nM. Fluticasone propionate shows little or no activity at other steroid receptors. Anti-viral activity.
    Fluticasone propionate-d3
Cat. No. Product Name / Synonyms Application Reactivity